ACTC Quote: "Now, we have follow-up that extends to longer than 3 years in patients treated with hESC-derived stem cells, showing both safety and apparent efficacy." "The studies by Schwartz and colleagues 1 show that the use of stem cell lines is a viable strategy."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.